Answers are grounded in this paper and cite their sources.
Changes in expression and dysfunctional signaling of TrkA/B/C receptors and oncogenic Trk fusion proteins are found in neurological diseases and cancers. Here, we describe the development of a first 18 F-labeled optimized lead suitable for in vivo imaging of Trk, [ 18 F]TRACK, which is radiosynthesized with ease from a nonactivated aryl precursor concurrently combining largely reduced P-gp liability and improved brain kinetics compared to previous leads while displaying high on-target affinity and human kinome selectivity.
No takes yet. Share an insight, caveat, or question.
Bernard‐Gauthier et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: